TY  - JOUR
AU  - Almeida, Ludmila Santiago
AU  - Etchebehere, Elba Cristina Sá de Camargo
AU  - García Megías, Irene
AU  - Calapaquí Terán, Adriana K
AU  - Hadaschik, Boris
AU  - Colletti, Patrick M
AU  - Herrmann, Ken
AU  - Giammarile, Francesco
AU  - Delgado Bolton, Roberto C
TI  - PSMA Radioligand Therapy in Prostate Cancer: Where Are We and Where Are We Heading?
JO  - Clinical nuclear medicine
VL  - 49
IS  - 1
SN  - 0363-9762
CY  - [Erscheinungsort nicht ermittelbar]
PB  - Ovid
M1  - DKFZ-2023-02180
SP  - 45-55
PY  - 2024
N1  - 2024 Jan 1;49(1):45-55
AB  - Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.
LB  - PUB:(DE-HGF)16
C6  - pmid:37882758
DO  - DOI:10.1097/RLU.0000000000004919
UR  - https://inrepo02.dkfz.de/record/285007
ER  -